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Cancer is a group of diseases characterised by 
uncontrolled growth and spread of abnormal cells, which 
can lead to death if left untreated1. The etiology of cancer 
can be associated with both external factors, including 
tobacco, infectious organisms, chemicals and radiation, 
as well as internal factors, such as inherited mutations, 
hormones, immune conditions and mutations occurring 
from metabolism2. These causal factors may act 
synergistically or sequentially to initiate or promote 
carcinogenesis3. 
Despite the considerable progress made over the last few 
decades in oncology research and treatment, cancer 
remains as one of the foremost causes of morbidity and 
mortality worldwide, with 12.7 million new cases and 
7.6 million deaths in 20084. More significantly, the most 
common cancer treatments are restricted to surgery, 
radiation and chemotherapy5, which are severely fraught 
with challenges concerned with adverse side effects of 
drugs6 due to their non-specific systemic distribution7, 
inadequate drug concentrations reaching the tumour8, 
intolerable toxicity9, and development of multiple drug 
resistance acquired upon repeated chemotherapeutic 
cycles10. Hence, there is clearly a need for novel 
chemotherapeutic agents with enhanced potency and 
specificity. 
To the best of our knowledge, no detailed studies have 
been reported on the pharmacological properties of 
Artabotrys crassifolius. Therefore, the objective in this 
research was to investigate the anticancer effects of 
crude extracts of Artabotrys crassifolius against human 
breast and colorectal carcinoma cell lines. 
MATERIALS AND METHODS 
Collection and identification of plant material 
The leaves and barks of Artabotrys crassifolius, with the 
local name of akar mempisang, were collected from 
Kuala Kangsar, Perak, Malaysia (4°46′N, 100°56′E) in 
March 2011. The plant was identified and authenticated 
by Mr. Kamarudin Saleh, Forest Biodiversity Division, 
Forest Research Institute Malaysia (FRIM). Voucher 
specimens were prepared and deposited in the Kepong 
Herbarium (KEP) of FRIM (PID 080311–05), and the 
School of Pharmacy, Faculty of Science, The University 
of Nottingham Malaysia Campus (UNMC 65) for future 
reference. 
Preparation of plant material 
After removal of extraneous matter, the freshly collected 
leaves and barks were air-dried in the shade at room 
temperature for at least 2 weeks. The dried leaves and 
barks were then finely pulverised by grinding prior to 
extraction. The pulverised leaves (1.30 kg) and barks 
(4.79 kg) were extracted sequentially with solvents of 
increasing polarity starting from hexane (Friendemann 
Schmidt, Australia), chloroform (Friendemann Schmidt, 
Australia) and 95% (v/v) of ethanol (John Kollin 
Chemicals, India). Each extraction was performed in 
triplicate at a solid-to-solvent ratio of 1:5 (w/v) in a 40°C 
water bath (Julabo, Germany) for three days. The 
respective extract was subsequently filtered through 
qualitative filter papers No. 1 (Whatman International 
Ltd., England) and the collected filtrate was concentrated 
to dryness under reduced pressure at 40°C using rotary 
evaporator (Buchi Labortechnik AG, Switzerland). 
Eventually, the dried extract obtained was weighed and 
stored at –20°C until further use. For stock solutions, 
each crude extract was dissolved in dimethyl sulphoxide 
(DMSO) (R & M Chemicals, UK) at a concentration of 
100 mg/mL and stored at 4°C. 
Cell lines and culture media 
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The cell lines used in the current study were derived 
from human carcinoma as shown in Table 1. Three 
human carcinoma cell lines were procured from the 
Centre for Biomolecular Sciences, School of Pharmacy, 
University of Nottingham UK Campus. 
 
Table 1: Types of human cell lines 
Human cell line 
Origin Designation 
Breast carcinoma MCF-7 (estrogen receptor-positive, ER+) 
Breast carcinoma MDA-468 (estrogen receptor-negative, ER–) 
Colorectal carcinoma HCT-116 
 
Each cell line was routinely maintained in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Sigma-
Aldrich, USA) supplemented with 2 mM of L-glutamine 
(Sigma-Aldrich, USA) and 10% (v/v) of foetal bovine 
serum (FBS) (Sigma-Aldrich, USA) at 37°C in a 
humidified 5% (v/v) of CO2 incubator (Binder, 
Germany), and subcultured twice weekly to maintain 
continuous logarithmic growth.   
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay 
The anticancer effects of crude extracts were investigated 
against human breast and colorectal carcinoma cell lines 
using MTT assay11,12. Each cell line was seeded in 96-
well microtiter plates (Jet Biofil, China) at a density of 5 
× 103 cells/well, and allowed to adhere for 24 h before 
crude extracts were introduced. Serial dilutions of crude 
extracts (final concentrations ranging from 6.25 µg/mL 
to 200 µg/mL) were prepared in medium immediately 
prior to assay. Viable cell masses at the time of crude 
extract addition (time zero) and following 72 h exposure 
were determined by cell-mediated reduction of MTT. A 
final concentration of 400 µg/mL of MTT (Sigma-
Aldrich, USA) was added to each well, and plates were 
incubated at 37°C for 4 h to allow reduction of MTT by 
viable cells to an insoluble formazan product. The well 
supernatant was subsequently aspirated and the cellular 
formazan was solubilised by addition of DMSO (R & M 
Chemicals, UK) and glycine buffer (pH 10.5) (Sigma-
Aldrich, USA) in a ratio of 4:1 (v/v). Eventually, the 
absorbance was read at 550 nm using an Anthos Labtec 
systems plate reader as a measure of cell viability. 
Using the eight absorbance measurements [time zero 
(Tz), control growth (C), and test growth in the presence 
of crude extracts at the six concentration levels (Ti)], the 
percentage growth was calculated at each of the crude 
extract concentration levels13. Percentage growth 
inhibition was calculated as: 
 
[(Ti – Tz)/(C – Tz)] × 100 for concentrations for which 
Ti ≥ Tz 
[(Ti – Tz)/Tz] × 100 for concentrations for which Ti < Tz 
 
Three dose response parameters were calculated for each 
crude extract. Growth inhibition of 50% (GI50) was 
calculated from [(Ti – Tz)/(C – Tz)] × 100 = 50, which 
was the crude extract concentration resulting in a 50% 
reduction in the net cell growth during the incubation. 
The crude extract concentration resulting in total growth 
inhibition (TGI) was calculated from Ti = Tz. The LC50 
(concentration of crude extract resulting in a 50% 
reduction of initial cells at the end of the treatment as 
compared to that at the beginning) indicating a net loss 
of cells following treatment was calculated from [(Ti – 
Tz)/Tz)] × 100 = –50. Values were calculated for each of 
these three parameters if the level of activity was reached; 
however, if the effect was not reached or was exceeded, 
the value for that parameter was expressed as greater or 
less than the maximum or minimum concentration 
tested14. 
Statistical analysis 
Statistical analysis of experimental data was performed 
using Microsoft Office Excel data analysis software. 
Data were presented by descriptive analysis as mean and 
standard deviation of three independent experiments 
performed in triplicate. 
RESULTS AND DISCUSSION 
Plants have an almost unlimited capacity to synthesize 
diverse secondary metabolites that attract researchers and 
scientists in the quest for new chemotherapeutics15. The 
continuing exploration for novel chemical classes of 
anticancer agents in medicinal plants is one of the 
realistic and promising approaches for cancer 
prevention16. In the present study, MTT assay was 
conducted to investigate the anticancer effects of crude 
extracts on the growth of human breast and colorectal 
carcinoma cell lines. 
This colourimetric assay is based on the capacity of 
mitochondrial succinate dehydrogenase enzymes in 
living cells to reduce the yellow water soluble substrate 
(MTT) into an insoluble, purple coloured formazan 
product which is measured spectrophotometrically. Since 
reduction of MTT can only occur in metabolically active 
cells, the level of activity is a measure of the cell 
viability17.  
According to the American National Cancer Institute 
(NCI), crude extracts could be considered as active for a 
GI50 value of less than 20 µg/mL
18. Based on the NCI 
criterion, chloroform extract of barks was highly active 
against all of the tested carcinoma cell lines with GI50 
values ranging from 4.23 µg/mL to 9.45 µg/mL (Figure 
1–3). Furthermore, hexane extract of barks potently 
inhibited the growth of MDA-468 breast carcinoma cell 
line as well as HCT-116 colorectal carcinoma cell line, 
with respective GI50 values of 6.10 µg/mL and 16.45 
µg/mL. This may indicate that the non-polar active 
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principles present in the barks are responsible for the anticancer activity of this plant. 
 
 
Figure 1: Effect of crude extracts of Artabotrys crassifolius on MCF-7 (ER+) breast carcinoma cell growth. 
Results are expressed as mean ± standard deviation (error bar) of three independent experiments performed in triplicate, 
n = 9. 
 
Figure 2: Effect of crude extracts of Artabotrys crassifolius on MDA-468 (ER–) breast carcinoma cell growth. 
Results are expressed as mean ± standard deviation (error bar) of three independent experiments performed in triplicate, 
n = 9. 
 
Figure 3: Effect of crude extracts of Artabotrys crassifolius on HCT-116 colorectal carcinoma cell growth. Results 
are expressed as mean ± standard deviation (error bar) of three independent experiments performed in triplicate, n = 9. 
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For better visualisation of the differences in achieving 
complete cell growth inhibition for all the crude extracts, 
TGI concentrations were expressed. In MCF-7 breast 
carcinoma cell line, chloroform and hexane extracts of 
barks were less potent as shown by their respective TGI 
values of 32.73 µg/mL and 54.63 µg/mL. In MDA-468 
breast carcinoma cell line, chloroform extract of barks 
induced total growth inhibition at the lowest 
concentration of 11.11 µg/mL, whereas hexane extract of 
barks displayed a comparable TGI value of 28.01 µg/mL. 
In HCT-116 colorectal carcinoma cell line, chloroform 
extract of barks exhibited a 1.75-fold lower TGI 
concentration than that of hexane extract of barks. 
However, no total growth inhibition was obtained upon 
treatment with ethanol extract of leaves and barks.  
 At doses higher than the TGIs, net cell killing was 
observed in all of the tested carcinoma cell lines. 
Chloroform extract of barks demonstrated the highest 
cytotoxic action with LC50 values ranging from 33.06 
µg/mL to 48.84 µg/mL, while hexane extract of barks 
showed less pronounced cytotoxicity with LC50 values 
ranging from 40.14 µg/mL to 105.61 µg/mL. 
Considering the TGI concentrations and the net cell 
killing achieved by crude extracts, MDA-468 breast 
carcinoma cell line was found to be the most sensitive 
cell line, followed by HCT-116 colorectal carcinoma cell 
line, with MCF-7 breast carcinoma cell line being the 
least responsive to crude extracts. 
 With respect to the phytochemical screening of crude 
extracts19, the presence of alkaloids, cardiac glycosides 
and terpenoids in chloroform and hexane extracts of 
barks may explain their superior activity compared to the 
other crude extracts tested. This necessitates further 
isolation and characterisation of the potentially active 
principles from the respective crude extracts. 
CONCLUSION 
Examination of the in vitro anticancer effect of 
Artabotrys crassifolius revealed that chloroform and 
hexane extracts of barks may be a significant source of 
novel anticancer compounds in view of their promising 
activities particularly against MDA-468 breast carcinoma 
cell line. Therefore, further studies need to be carried out 
to isolate and characterise the bioactive compounds 
responsible for the observed anticancer properties of 
Artabotrys crassifolius. 
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